Clearmind Medicine engages lobbying firm to advance psychedelic therapeutics

Clearmind Medicine (CMND) has engaged a government and political affairs consulting and lobbying firm to support its mission of advancing psychedelic-based treatments. As psychedelics gain traction in the pharmaceutical industry for their potential to treat conditions such as Post-Traumatic Stress Disorder and other mental health disorders, Clearmind recognizes the importance of navigating complex regulatory landscapes and fostering greater acceptance among policymakers in the U.S. The Company has partnered with the firm to help advance the integration of psychedelic therapies into mainstream healthcare by advocating for informed, science-based regulatory frameworks. The consulting firm will work closely with Clearmind to educate policymakers on the therapeutic potential of psychedelics, support the development of balanced regulations, and foster strategic alliances to advance the Company’s pipeline, including its lead candidate, CMND-100, currently in Phase I/IIa clinical trials for AUD at institutions like Yale School of Medicine and Johns Hopkins University.